Table 1.
Clinical demographics of HCC patients and comparison of the characteristics of patients with minimal or advanced fibrosis
| All patients (n = 76) | Minimal fibrosis (n = 14) | Advanced fibrosis (n = 62) | P* | |
|---|---|---|---|---|
| Patient demographics | ||||
| Age (y/o) (median 25 and 75 percentiles) | 57.0; 46.3–68.0 | 53.0; 34.8–68.8 | 58.0; 46.8–68.0 | 0.348 |
| Sex (M:F) | 64:12 | 13:1 | 51:11 | 0.447 |
| Body mass index (kg/m2) (median 25 and 75 percentiles) | 23.3; 21.0–25.6 | 22.1, 21.2–24.9 | 23.5; 20.9–26.3 | 0.440 |
| Albumin (g/dL) (median 25 and 75 percentiles) | 4.0; 3.7–4.2 | 4.2; 4.1–4.4 | 3.9; 3.7–4.2 | 0.011 |
| Total bilirubin (mg/dL) (median 25 and 75 percentiles) | 1.0; 0.8–1.3 | 0.9; 0.7–1.1 | 1.0; 0.8–1.4 | 0.079 |
| ALT (U/L) (median 25 and 75 percentiles) | 51.0; 29.0–81.8 | 27.0; 18.3–40.5 | 58.0; 36.0–112.3 | 0.001 |
| AST (U/L) (median 25 and 75 percentiles) | 43.0; 29.3–71.5 | 25.0; 19.5–29.5 | 50.5; 34.0–76.3 | <0.001 |
| ICG-15R (%) (retention rate) (median 25 and 75 percentiles) | 12; 9–20 | 5; 3–9 | 13; 10–21 | <0.001 |
| PT INR (median 25 and 75 percentiles) | 1.02; 1.00–1.20 | 1.01; 0.94–1.14 | 1.02; 1.00–1.20 | 0.282 |
| Platelet (mm−3) (median 25 and 75 percentiles) | 140,000; 93,000–183,750 | 178,000; 138,250–226,500 | 132,000; 86,750–176,500 | 0.005 |
| APRI (median 25 and 75 percentiles) | 0.81; 0.40–1.53 | 0.31; 0.18–0.43 | 0.97; 0.56–1.73 | <0.001 |
| Child–Pugh A/B (%) | 69/7 (90.8/9.2) | 14/0 (100/0) | 55/7 (88.7/11.3) | 0.337 |
| Viral factors | ||||
| HBeAg (positive/negative) | 9/56 | 0/12 | 9/44 | 0.191 |
| HBV DNA (copies/mL) (median; 25 and 75 percentiles) | 453,500; 37,100–1.64 × 107 | 150,000; 17,950–2.13 × 106 | 2,170,000; 405,00–3.45 × 107 | 0.163 |
| Genotype B/C | 38/35 | 6/8 | 32/27 | 0.639 |
| Tumor characteristics | ||||
| Tumor size (cm) (median 25 and 75 percentiles) | 2.5; 2.0–3.2 | 3.0; 1.9–4.0 | 2.5; 2.0–3.1 | 0.427 |
| AFP (ng/ml) (median 25 and 75 percentiles) | 38.5; 8.5–638.3 | 72.0; 4.8–1151.3 | 35.0; 9.5–480.0 | 0.888 |
| Macroscopic venous invasion (%) | 5 (6.6%) | 0 (0%) | 5 (8.1%) | 0.577 |
| Cut margin ≤1 cm/>1 cm | 39 (61.9%) | 8 (57.1%) | 31 (63.3%) | 0.917 |
| Histo-pathological findings | ||||
| Edmondson grading (I/II/III/IV) | 6/48/14/1 | 1/9/3/0 | 5/39/11/1 | 0.958 |
| Microscopic venous invasion (%) | 58 (76.3%) | 11 (78.6%) | 47 (75.8%) | 1.000 |
| Capsule formation | 15 (25.4%) | 1 (10%) | 14 (28.6%) | 0.426 |
| Satellite lesions (%) | 31 (56.4%) | 8 (72.7%) | 23 (52.3%) | 0.314 |
| Ishak score-inflammation (median 25 and 75 percentiles) | 6.3 ± 3.3 | 2.9 ± 1.2 | 7.1 ± 3.1 | <0.001 |
ICG-15R indocyanine green retention rate at 15 min, PT prothrombin time, INR international normalized ratio, APRI aspartate aminotransferase–platelet ratio index
* P value: comparison between minimal and advanced fibrosis